https://www.selleckchem.com/pr....oducts/tenapanor.htm
The concentration of nanoplaques in the CSF differentiates patients with clinical AD from non-AD patients. The concentration of nanoplaques in the CSF differentiates patients with clinical AD from non-AD patients. In the treatment of Alzheimer's disease (AD), it is thought to be most effective to intervene at the earliest and mildest stages. For diagnosis at the earliest and mildest stages, it is desirable to use a biomarker that can be detected by a minimally invasive, cost-effective technique. Recent research indicates the potential
Like
Comment
Share
